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OBJECTIVE: Chronic non-cancer pain (CNCP) is a 
condition that may result in high healthcare costs 
and reduced workplace productivity. The objective of 
this study was to quantify work loss and pain-related
healthcare utilization among employees with CNCP.
METHODS: A retrospective analysis was conducted
using the MEDSTAT Health and Productivity Manage-
ment database, which includes absences, worker’s com-
pensation and short-term disability claims for employees
from six large U.S. corporations along with inpatient,
outpatient, and pharmacy claims from 1997–1999. Pres-
ence of CNCP was deﬁned as 90+ days supply of opioids
within the study period and a pain-related diagnosis.
Workdays lost (absences plus short-term disability) were
converted to dollars ($US1998) using location-speciﬁc
wage rates from the US Bureau of Labor Statistics.
Healthcare utilization included opioid usage, pain-related
outpatient medical visits, and pain-related inpatient 
hospitalizations. RESULTS: From the original outpatient
data ﬁle of 236,736 employees, 2,459 had CNCP and
were eligible to have work loss data reported, of which
1,512 experienced sickness absence(s) and/or short-term
disability days. Those with work loss experienced a
longer median duration of pain than those without work
loss (887 vs. 934.5 days). Pain-related direct costs were
$5378 per employee per year. Indirect costs (wages lost
per employee per year) were $5339–$7475, based on sen-
sitivity analyses. The total impact of CNCP for employ-
ees whose work loss was recorded was at least $2.1
million per employer per year. CONCLUSIONS: Few
data have been compiled to examine the economic impact
of CNCP speciﬁcally to employers. The ﬁndings demon-
strate that CNCP is associated with signiﬁcant resource
consumption and lost workdays, and suggest a need for
employer-sponsored pain management programs.
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OBJECTIVES: This analysis quantiﬁes the prevalence,
health beneﬁts cost, and real productivity loss experi-
enced by employees as a result of allergies. Healthcare
claims and employee population data are used to quan-
tify the prevalence of respiratory system allergies. Addi-
tionally, demographic, health beneﬁts, and output-based
productivity data are used to compare the health beneﬁts
cost and productivity of employees with and without
allergies. METHODS: Using data from October 2000 to
September 2002, this study examines 86,000 geographi-
cally-disperse employees. An employee was deﬁned to
have an allergy diagnosis if the employee had a health-
care claim with a primary ICD9 code of 477.xx or
493.0x. Logistic regression was used to determine the
demographic factors that were associated with the 
likelihood of ﬁling an allergy claim. In addition, tobit 
and linear regression models were used to determine the
isolated impact of an allergy diagnosis on an employee’s
health beneﬁts cost and productivity output. RESULTS:
Of the employee population examined, 17.3% were diag-
nosed with allergies during the 2-year period. An allergy
diagnosis was associated with a subsequent isolated
increase of $106 per month (p < 0.001) in the employee’s
total beneﬁts cost (including healthcare, prescription
drug, sick leave, short- and long-term disability, and
workers’ compensation). Similarly, an allergy diagnosis
was associated with a subsequent isolated decrease in pro-
ductivity (units processed per hour) of 2.7% (p < 0.001).
CONCLUSIONS: Nearly one in six employees were diag-
nosed with allergies during the study period, resulting in
signiﬁcantly higher costs to the employer and signiﬁcantly
lower productivity. Employers will use this information
to more accurately assess the beneﬁts of supporting 
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OBJECTIVES: Recently reported rates of Medicare ben-
eﬁciaries restricting prescription medication use because
of cost ranges from 1.6 to 22%. A reliable estimate of
prescription non-procurement due to cost and an under-
standing of this behavior is essential to appropriate policy
development. METHODS: The 2000 Health and 
Retirement Study, nationally representative of Americans
born before 1947, provides cross-sectional data regard-
ing respondent insurance coverage and prescription 
non-procurement. All non-institutionalized, Medicare
beneﬁciaries age 65 and older were identiﬁed. Weighted
bivariate analysis and multivariate stepwise logistic
regression modeling determined the association and inde-
pendent predictive value of several risk factors, including
total health insurance coverage, on prescription non-
procurement. RESULTS: Data for 9771 respondents were
identiﬁed. Prescription non-procurement due to cost was
reported in 4.5%, 8.5%, and 9.8% of respondents with
Medicare plus private insurance, Medicare only, and
Medicare plus Medicaid, respectively. Bivariate analysis
revealed similar risk factor-related trends both within and
between health insurance categories. The ﬁnal regression
model included several signiﬁcant factors (p < 0.0001)
predictive of non-procurement, the most notable being
income, number of symptoms, and total prescription
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costs. In this model, prescription non-procurement was
more likely to be reported in the Medicare-only popula-
tion (OR: 1.47; 95% CI 1.46–1.48) and in the Medicare
plus Medicaid population (OR: 1.11; 95% CI 1.10–1.12)
as compared to respondents with Medicare plus private
insurance coverage. CONCLUSIONS: Signiﬁcantly dif-
ferent rates of persons who forego ﬁlling a prescription
for cost reasons were observed among Medicare beneﬁ-
ciaries. More vulnerable groups of seniors were identiﬁed.
Dual eligible Medicare/Medicaid enrollees and those with
Medicare alone are more likely to restrict medication 
procurement due to cost.
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OBJECTIVES: 1) To explore 1-year persistence pattern
of Overactive Bladder/Urinary Incontinence (OAB/UI)
medication treatment; 2) to discover factors associated
with persistence; and 3) to investigate the beneﬁt of reﬁll
adherence on urinary track infection (UTI). METHODS:
Retrospective analyses on continuously enrolled adult
patients diagnosed with OAB/UI and received at least one
OAB/UI medication from July 1999 to April 2001 (with
6-month run-in period and 1-year follow-up period) are
employed. Time to discontinuity, deﬁned as the period
from the index date to the discontinuity date (when any
medication-uncovered interval is longer than 30 days), 
is used to describe the persistence pattern of patients.
Adherence is measured by medication possession ratio
(MPR). A Cox Proportional Hazard model is applied to
reveal risk factors of non-persistence. A logistic regression
is used to examine the relationship of those same factors
with reﬁll adherence and to assess the effect of adherence
on UTI incidence rate. RESULTS: Of 6518 eligible
patients, 26.8% have only 1 prescription. 5751 patients
(88.2%) discontinue within the following year, among
which, 92.2% fail to continue treatment after 183 days.
Only 952 patients (14.6%) exhibit good adherence (MPR
>= 0.8). The mean MPR of the whole cohort is 0.39 and
the median is 0.24. Signiﬁcant predictors of higher per-
sistence include Caucasians, 75 years old or above, prior
medication use, and initiating extended-release form of
drug. Patients with prior prescription of antidepressant or
diagnosis of depression show lower persistence. Similar
results are found for adherence. Logistic regression indi-
cates that good reﬁll adherence reduces the risk of being
diagnosed with UTI by 33% in the post-treatment period
(P = 0.0008, OR = 0.672). CONCLUSIONS: Both 
persistence of OAB/UI medication and reﬁll adherence 
are low, suggesting the need to develop effective inter-
ventions in OAB/UI and UTI.
AD3
PREDICTIVE MODEL OF MEDICATION
ADHERENCE IN CARDIOVASCULAR DISEASE
Chen KS1, Leslie RS1, Chang E1, Fairchild C2
1Prescription Solutions, Costa Mesa, CA, USA; 2Bristol-Myers
Squibb, Plainsboro, NJ, USA
OBJECTIVES: Medication non-compliance has been a
growing concern for healthcare management and can
result in progression of cardiovascular disease (CV) and
an increase in economic burden. To develop models to
predict the risk for future medication non-compliance
among patients with hypertension and hyperlipidemia.
METHODS: Two predictive models were constructed
using pharmacy and medical claims from 2380 patients
newly treated with anti-hypertensive medications and
3387 patients newly treated with statins in a managed
care setting. The outcomes of interest were the future
medication compliance rates for both disease states over
a one-year follow-up period. The potential predictors of
compliance included patient characteristics such as age,
gender, type of insurance plan, Chronic Disease Score
(CDS), presence of select comorbidities, copayments,
total medication burden, hospital encounters, outpatient
physician encounters, and initial compliance (0–3 months
of therapy immediately before the follow-up period).
Linear regression models were applied to construct the
models. Each population was randomly split by a 2 to 1
ratio to facilitate spilt-sample validation of the models.
RESULTS: Based on the hypertension model, age, gender,
total co-payments, total medication burden, and initial
compliance showed signiﬁcant relationship with compli-
ance (R2 = 0.45). Based on the hyperlipidemic model, age,
gender, presence of a second CV condition (e.g. angina),
outpatient physician encounters, co-payments at drug ini-
tiation, total medication burden, and initial compliance
demonstrated signiﬁcant relationship with compliance
(R2 = 0.43). In both populations, initial compliance was
the strongest predictor of sustained compliance. CON-
CLUSION: These models can serve as a useful tool to
guide providers in promoting medication compliance.
Both models suggest that assisting the patient to establish
compliant behavior within the ﬁrst three months of a new
treatment regimen can signiﬁcantly inﬂuence sustained
medication adherence with CV medications.
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